Brief: Mural Oncology Announces Enhancements To Late-Stage Clinical Trials
08/01/2024 13:50
Jan 8 (Reuters) - Mural Oncology PLC MURA.O :
* MURAL ONCOLOGY ANNOUNCES ENHANCEMENTS TO LATE-STAGE
CLINICAL
TRIALS
* STRATEGIC CHANGES TO ARTISTRY-6 AND ARTISTRY-7 CLINICAL
TRIALS
DESIGNED TO GENERATE MORE MEANINGFUL CLINICAL DATA FOR
LATE-STAGE
* INTENDS TO NOMINATE DEVELOPMENT CANDIDATES FOR ENGINEERED
THERAPIES TARGETING INTERLEUKIN-18 AND INTERLEUKIN-12 PROGRAMS
IN 2024
* REITERATES CURRENT CASH RUNWAY PROJECTION INTO 4Q 2025
Source text for Eikon: ID:nGNX65RcCr
Further company coverage: MURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mural Oncology
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM